An innovative alpha-radiation cancer therapy has been administered for the first time to a Hadassah Medical Organization patient with recurrent lung cancer.
The clinical trial is designed to treat up to 10 patients with recurrent tumors in the mediastinum area of the chest, FirstWord Pharma reports. The study will assess the safety and feasibility of delivering Alpha DaRT sources into the lung using an endobronchial ultrasound (EBUS) procedure.
“Treating the first patient with lung cancer using Alpha DaRT marks a significant advancement, introducing a novel approach that combines the precision of alpha-emitting particles with the ability to selectively target and destroy tumor cells while minimizing damage to surrounding healthy tissues,” said Dr. Philip Blumenfeld, study co-investigator and senior radiation oncologist and head of Thoracic Radiation Oncology Services at the Hadassah Medical Organization.
“In this specific case, the patient had already undergone conventional radiation therapy to the lung and lymph nodes, and additional radiation would have posed a high risk of serious harm to nearby structures, particularly the esophagus and bronchus.”
“We look forward to further examining the promise of what the Alpha DaRT treatment can offer lung cancer patients and their families,” said Prof. Neville Berkman, MD, the study’s principal investigator and director of Hadassah’s Institute of Pulmonology.
Read the full story in FirstWord Pharma.
Read More
Israel's Health Ministry Approves Program to Detect Lung Cancer Earlier
Hadassah Excels in Cancer Research and Treatment
Women With Ovarian Cancer Find Hope at Hadassah